ALERT: NRx Pharmaceuticals, Inc. Investors Suffering Substantial Losses Have Opportunity to File Class Action – NRXP; NRXPW

SAN DIEGO–(BUSINESS WIRE)–Robbins Geller Rudman & Dowd LLP announces that purchasers of securities of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP; NRXPW) between June 1, 2021 and November 4, 2021 inclusive (the “Class Period”) have until March 21, 2022 to request a nomination as lead applicant in Dal Bosco c. NRx Pharmaceuticals, Inc., no. 22-cv-00066 (D. Del.). Started on January 18, 2022, the NRx Pharma The class action accuses NRx and some of its top executives of violating the Securities Exchange Act of 1934.

If you have suffered significant losses and wish to act as the lead plaintiff of the NRx Pharma class action, please provide your information by clicking here. You can also contact attorney JC Sanchez of Robbins Geller by calling 800/449-4900 or emailing [email protected] Principal Applicant’s Requests for NRx Pharma the class action must be filed with the court no later than March 21, 2022.

CASE ALLEGATIONS: NRx is a clinical-stage small molecule pharmaceutical company developing various therapies for the treatment of central nervous system disorders and life-threatening lung diseases. NRx’s products include, among others, ZYESAMI, an investigational pre-market drug for respiratory failure related to COVID-19. In June 2021, NRx announced that it had filed an application with the United States Food and Drug Administration (“FDA”) seeking an Emergency Use Authorization (“EUA”) for ZYESAMI (Aviptadil-acetate) to treat critically ill COVID-19 patients with respiratory conditions. failure.

the NRx Pharma The Class Action alleges that, throughout the Class Period, the Defendants made false and misleading statements and failed to disclose that: (i) ZYESAMI’s EUA Application contained insufficient data regarding the benefits and the potential risks of ZYESAMI; (ii) as a result, the FDA was unlikely to approve ZYESAMI’s EUA application in its current form; and (iii) therefore, NRx’s public statements were materially false and misleading at all relevant times.

On November 4, 2021, NRx issued a press release “announcing[ing] that the [FDA] refused to issue a [EUA] for ZYESAMI® (aviptadil). The FDA has said it is unable to issue the EUA at this time due to insufficient data regarding the known and potential benefits of the drug and the known and potential risks of ZYESAMI in patients with COVID-19. critical with respiratory failure. At this news, NRx’s stock price fell more than 25%, hurting investors.

Robbins Geller Rudman & Dowd LLP launched a dedicated SPAC working group to protect investors in blank check companies and seek redress for corporate wrongdoing. Comprised of experienced litigators, investigators and forensic accountants, the SPAC Task Force is dedicated to researching and prosecuting fraud on behalf of aggrieved SPAC investors. The rise of blank check funding presents unique risks for investors. Robbins Geller’s SPAC Task Force represents the forefront of ensuring integrity, honesty and fairness in this rapidly developing area of ​​investment.

THE PRINCIPAL APPLICANT PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased NRx securities during the Class Period to seek appointment as lead plaintiff in the NRx Pharma class action. A principal plaintiff is generally the plaintiff with the greatest financial interest in the remedy sought by the putative class that is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members by directing the NRx Pharma class action. The main plaintiff can select a law firm of his choice to plead NRx Pharma class action. An investor’s ability to participate in any potential future upturn in the NRx Pharma to classify legal action does not depend on the status of principal plaintiff.

ABOUT ROBBINS GELLER RUDMAN & DOWD LLP: With 200 attorneys in 9 offices across the country, Robbins Geller Rudman & Dowd LLP is the largest US law firm representing investors in securities class actions. Robbins Geller’s lawyers secured many of the largest shareholder recoveries in history, including the largest ever securities class action lawsuit – $7.2 billion – in In re Enron Corp. Dry. Dispute. The 2020 ISS Securities Class Action Services Top 50 report ranked Robbins Geller first for recovering $1.6 billion for investors that year, more than double the amount recovered by any other securities plaintiff firm. . Please visit for more information.

Lawyer advertisement.

Past results do not guarantee future results.

Services can be performed by attorneys in any of our offices.

Comments are closed.